Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality

[1]  M. Müllner,et al.  Vasopressors for hypotensive shock. , 2016, The Cochrane database of systematic reviews.

[2]  K. Sliwa,et al.  Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance , 2016, Intensive Care Medicine.

[3]  Wen Jiang,et al.  Predictive value of EEG-awakening for behavioral awakening from coma , 2015, Annals of Intensive Care.

[4]  Ying Luo,et al.  [Propensity score matching in SPSS]. , 2015, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[5]  A. Mebazaa,et al.  Experts’ recommendations for the management of adult patients with cardiogenic shock , 2015, Annals of Intensive Care.

[6]  E. Ohman,et al.  Management of cardiogenic shock. , 2015, European heart journal.

[7]  Holger Thiele,et al.  Clinical picture and risk prediction of short‐term mortality in cardiogenic shock , 2015, European journal of heart failure.

[8]  Deepak L. Bhatt,et al.  Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure: Insights From Get With The Guidelines , 2014, Circulation. Heart failure.

[9]  J. Haerting,et al.  Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. , 2014, The Cochrane database of systematic reviews.

[10]  Adrian F Hernandez,et al.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.

[11]  G. Schuler,et al.  Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial , 2013, The Lancet.

[12]  Peter C Austin,et al.  A comparison of 12 algorithms for matching on the propensity score , 2013, Statistics in medicine.

[13]  A. Mebazaa,et al.  The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis , 2013, PloS one.

[14]  E. Lang,et al.  Vasopressors for hypotensive shock. , 2013, Annals of emergency medicine.

[15]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[16]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[17]  K. Subramaniam,et al.  Mechanical circulatory support for cardiogenic shock. , 2012, Best practice & research. Clinical anaesthesiology.

[18]  S. Hollenberg,et al.  Vasoactive drugs in circulatory shock. , 2011, American journal of respiratory and critical care medicine.

[19]  B. Levy,et al.  Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study* , 2011, Critical care medicine.

[20]  G. Patel,et al.  EFFICACY AND SAFETY OF DOPAMINE VERSUS NOREPINEPHRINE IN THE MANAGEMENT OF SEPTIC SHOCK , 2010, Shock.

[21]  J. Vincent,et al.  Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.

[22]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[23]  J. Gore,et al.  Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial Infarction: A Population-Based Perspective , 2009, Circulation.

[24]  M. Pfisterer,et al.  Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock , 2008, Annals of Internal Medicine.

[25]  Therapy Study Investigators,et al.  A comparison of epinephrine and norepinephrine in critically ill patients , 2008, Intensive Care Medicine.

[26]  Judith S. Hochman,et al.  Cardiogenic Shock: Current Concepts and Improving Outcomes , 2008, Circulation.

[27]  G. Felker,et al.  Inotropes in the management of acute heart failure , 2008, Critical care medicine.

[28]  M. Singer.  Catecholamine treatment for shock—equally good or bad? , 2007, The Lancet.

[29]  R. D'Agostino.  Propensity Scores in Cardiovascular Research , 2007, Circulation.

[30]  Didier Payen,et al.  Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study* , 2006, Critical care medicine.

[31]  M. Gheorghiade,et al.  Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.

[32]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[33]  R. Bellomo,et al.  Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial , 2000, The Lancet.

[34]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[35]  J. Vincent,et al.  Circulatory shock. , 2013, The New England journal of medicine.

[36]  M. Gheorghiade,et al.  Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. , 2007, American heart journal.